Cover Image
市場調查報告書

急性骨髓性白血病(AML,急性骨髓芽球性白血病) : 開發中產品分析

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 232771
出版日期 內容資訊 英文 2103 Pages
訂單完成後即時交付
價格
Back to Top
急性骨髓性白血病(AML,急性骨髓芽球性白血病) : 開發中產品分析 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2018
出版日期: 2018年06月29日 內容資訊: 英文 2103 Pages
簡介

急性骨髓性白血病(AML)一般較常見的名字是急性骨髓芽球性白血病,是侵害血液及骨髓的疾病。由於未成熟的白血球積蓄在骨髓,妨礙了正常血液細胞的產生。這些細胞將進入血液並擴及全身。其常見的症狀有疲勞感、發熱、出血、呼吸困難、體重減少等。相關的致病因素有曝曬於放射線或化學物質,以及抽煙等。某種特定的血液疾病結果也可能引發AML之外的疾病。治療有化療、輸血、移植、藥物療法等。

本報告提供急性骨髓性白血病(AML)的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您涵括了最新的新聞和發表之企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

急性骨髓性白血病(AML,急性骨髓芽球性白血病)概要

治療藥的開發

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

企業開發中的產品

大學/機關研究中的產品

治療藥的開發企業

治療藥的評估

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC10528IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2018, provides an overview of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) pipeline landscape.

Acute myelocytic leukemia (AML), also known as acute myelogenous leukemia is a type of cancer that affects the blood and the bone marrow. Immature white blood cells accumulate in the bone marrow thus blocking the production of normal blood cells. These cells further enter the blood stream and spread to the other parts of the body. Symptoms for AML include fatigue, fever, bleeding, breathing problems, weight loss. The predisposing factors involved are exposure to radiation or chemicals and smoking. Treatment includes chemotherapy, transfusions, transplant and surgery.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 1, 16, 120, 105, 7, 171, 24 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 18, 16, 1, 35 and 18 molecules, respectively.

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Overview
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics Development
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics Assessment
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Companies Involved in Therapeutics Development
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Drug Profiles
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Discontinued Products
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Stage and Target, H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by 4SC AG, H1 2018
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2018
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AB Science SA, H1 2018
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AbbVie Inc, H1 2018
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Actinium Pharmaceuticals Inc, H1 2018
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ADC Therapeutics SA, H1 2018
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Advenchen Laboratories LLC, H1 2018
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aeglea BioTherapeutics Inc, H1 2018
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Affichem SA, H1 2018
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Agios Pharmaceuticals Inc, H1 2018
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aileron Therapeutics Inc, H1 2018
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AIMM Therapeutics BV, H1 2018
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AlfaSigma SpA, H1 2018
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Altor BioScience Corp, H1 2018
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Amgen Inc, H1 2018
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Amplia Therapeutics Pty Ltd, H1 2018
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Angiocrine Bioscience Inc, H1 2018
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Antigen Express Inc, H1 2018
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Antisense Therapeutics Ltd, H1 2018
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by APIM Therapeutics AS, H1 2018
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aprea AB, H1 2018
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aptevo Therapeutics Inc, H1 2018
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by arGEN-X BV, H1 2018
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Ariad Pharmaceuticals Inc, H1 2018
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Arog Pharmaceuticals Inc, H1 2018
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Array BioPharma Inc, H1 2018
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Arrien Pharmaceuticals LLC, H1 2018
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Ascentage Pharma Group Corp Ltd, H1 2018

List of Figures

  • Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Top 10 Targets, H1 2018
  • Number of Products by Stage and Top 10 Targets, H1 2018
  • Number of Products by Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Top 10 Routes of Administration, H1 2018
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2018
  • Number of Products by Top 10 Molecule Types, H1 2018
  • Number of Products by Stage and Top 10 Molecule Types, H1 2018
Back to Top